

# Therapeutic efficacy of tumor-targeting *Salmonella typhimurium* A1-R on human colorectal cancer liver metastasis in orthotopic nude-mouse models

Takashi Murakami<sup>1,2,3</sup>, Yukihiro Hiroshima<sup>1,2,3</sup>, Ming Zhao<sup>1</sup>, Yong Zhang<sup>1</sup>, Takashi Chishima<sup>3</sup>, Kuniya Tanaka<sup>3</sup>, Michael Bouvet<sup>2</sup>, Itaru Endo<sup>3</sup>, Robert M. Hoffman<sup>1,2</sup>

<sup>1</sup>AntiCancer, Inc., San Diego, California, USA

<sup>2</sup>Department of Surgery, University of California San Diego, California, USA

<sup>3</sup>Department of Gastroenterological Surgery, Graduate School of Medicine, Yokohama City University, Yokohama, Japan

## Correspondence to:

Robert M. Hoffman, e-mail: all@anticancer.com

**Keywords:** nude mice, orthotopic, liver metastasis, red fluorescent protein, *Salmonella typhimurium* A1-R

**Received:** June 30, 2015

**Accepted:** August 25, 2015

**Published:** September 07, 2015

## ABSTRACT

**Liver metastasis is the most frequent cause of death from colon and other cancers. Generally, liver metastasis is recalcitrant to treatment. The aim of this study is to determine the efficacy of tumor-targeting *Salmonella typhimurium* A1-R on liver metastasis in orthotopic mouse models. HT-29 human colon cancer cells expressing red fluorescent protein (RFP) were used in the present study. *S. typhimurium* A1-R infected HT-29 cells in a time-dependent manner, inhibiting cancer-cell proliferation *in vitro*. *S. typhimurium* A1-R promoted tumor necrosis and inhibited tumor growth in a subcutaneous tumor mouse model of HT-29-RFP. In orthotopic mouse models, *S. typhimurium* A1-R targeted liver metastases and significantly reduced their growth. The results of this study demonstrate the future clinical potential of *S. typhimurium* A1-R targeting of liver metastasis.**

## INTRODUCTION

Anecdotal records go back hundreds of years describing patients having their cancer go into remission after a bacterial infection [1]. In 1867, the German physician Busch reported that a cancer patient went into remission after contracting erysipelas, now known as *Streptococcus pyogenes* [2]. Bruns treated a cancer patient in 1888 with *S. pyogenes* and the tumor regressed [1]. Koch, Pasteur and von Behring recorded that cancer patients infected with *S. pyogenes* had tumor regression [1].

In the 1890s, William B. Coley of New York Cancer Hospital, which became Sloan-Kettering Memorial Cancer Center, treated cancer patients with *S. pyogenes*. Coley had excellent results infecting cancer patients with *S. pyogenes*. Hoption Cann et al. [3] compared Coley's bacterial treatment to current chemotherapy and found the 10-year survival rates of Coley's patients were comparable [4] to current conventional therapies [4].

Malmgren and Flanigan [5] demonstrated that anaerobic bacteria could survive and replicate in necrotic tumor tissue which had low oxygen content. Several other early approaches aimed at utilizing bacteria for cancer therapy in animal models were described [6–16].

The obligate anaerobes *Bifidobacterium* [17] and *Clostridium* [18], which replicate only in necrotic areas of tumors, have been tested for cancer therapy in mouse models. *Bifidobacterium longum* selectively localized in mammary tumors after systemic administration [17]. Spores of *Clostridium novyi*, without its lethal toxin (*C. novyi* no toxin [NT]), germinated within necrotic areas of tumors in mice and, in combination with chemotherapy, resulted in hemorrhagic necrosis and tumors regression [18]. Recently, *C. novyi*-NT was used in a patient with leiomyosarcoma and caused one metastatic lesion to regress [19].

*Salmonella typhimurium* (*S. typhimurium*) is a facultative anaerobe which, in contrast to obligate anaerobes, can grow in the viable regions as well

as necrotic regions of tumors [20]. *S. typhimurium* with a lipid A—mutation (msbB) deletion along with purine auxotrophic mutations (purI) had antitumor efficacy in mice [21]. *S. typhimurium* (VNP20009), with msbB and purI mutations, was relatively safely administered to patients in a Phase I clinical trial on patients with metastatic melanoma and renal carcinoma. Overattenuation perhaps limited efficacy [22].

Liver metastases is the most frequent cause of death of patients with colorectal cancer [23]. Hepatectomy is the most effective treatment for liver metastasis from colorectal cancer, but the recurrence rate is over 50% after resection [24]. In addition, efficacy of chemotherapeutic agents are marginal [25]. Therefore, development of effective treatment for liver metastasis is urgently needed.

The tumor-targeting *S. typhimurium* A1-R strain developed by our laboratory has high tumor colonization and antitumor efficacy. *S. typhimurium* A1-R is auxotrophic for leu-arg, which prevents it from mounting a continuous infection in normal tissues. *S. typhimurium* A1-R was able to inhibit or eradicate primary and metastatic tumors as monotherapy in nude mouse models of prostate [26, 27], breast [28–30], lung [31, 32], pancreatic [33–37], ovarian [38, 39], stomach [40] and cervical cancer [41], as well as sarcoma [42–45] and glioma [46, 47], all of which are highly aggressive tumor models.

The present report demonstrates efficacy of *S. typhimurium* A1-R on liver metastasis of colon cancer in orthotopic mouse models.

## RESULTS AND DISCUSSION

### *S. typhimurium* A1-R targeted HT-29 colon cancer cells *in vitro*

*S. typhimurium* A1-R-GFP infection of HT-29 cells expressing red fluorescent protein (HT-29-RFP) was observed beginning 1 hour after addition of bacteria to the cultures (Figure 1A–1B). At 15 hours after addition, many *S. typhimurium* A1-R-GFP cells were observed inside the HT-29 cancer cells (Figure 1C).

### *S. typhimurium* A1-R inhibited HT-29 cancer cell proliferation *in vitro*

HT-29-RFP cancer cell colonies were significantly reduced by *S. typhimurium* A1-R-GFP both in area (Figure 1D) and number (Figure 1E) ( $P < 0.01$  for both).

### Efficacy of *S. typhimurium* A1-R on subcutaneous HT-29 tumor growth

Subcutaneous tumor growth was significantly inhibited after the 3<sup>rd</sup> i.v. administration of *S. typhimurium* A1-R. The tumor volume ratio at day 22 compared to day 1 in the control

group was  $6.17 \pm 1.16$  and  $2.68 \pm 0.73$  in the *S. typhimurium* A1-R treatment group,  $P < 0.05$  (Figure 2A–2D). Resected specimens showed *S. typhimurium* A1-R induced more extensive necrosis in the tumors compared to those without treatment (Figure 2E–2H).

### Efficacy of *S. typhimurium* A1-R on orthotopic liver metastasis mouse models

*S. typhimurium* A1-R-GFP targeted the liver metastasis 3 days after the 2<sup>nd</sup> i.v. administration of *S. typhimurium* A1-R (Figure 3). *S. typhimurium* A1-R treatment significantly suppressed metastatic progression compared to the control group at day 22. The metastasis fluorescent area ratio on day 22 compared to day 1 was  $5.69 \pm 0.83$  in the *S. typhimurium* A1-R treatment group and  $12.96 \pm 1.49$ , in the untreated control group ( $P < 0.01$ ; Figure 4).

The present study demonstrated that tumor-targeting *S. typhimurium* A1-R has significant efficacy on liver metastasis in orthotopic mouse models, suggesting clinical activity for patients with colorectal liver metastasis. The present study suggests *S. typhimurium* A1-R may also be useful in the neo-adjuvant setting to reduce the liver metastasis that would make previously inoperable liver metastasis resectable.


Spleen injection selects colon cancer cells which can grow in the liver. However, this leads to multiple metastatic sites, which were harvested to directly implant a single metastases on the liver of additional mice, which was the desired model. Future experiments will treat models with multiple liver metastases with *S. typhimurium* A1-R.

This is the first study to use *S. typhimurium* A1-R to treat colon cancer liver metastasis, which occurs at high frequency and is usually the cause of lethality of this disease. The significant efficacy of *S. typhimurium* A1-R on the liver metastasis was comparable to the efficacy of *S. typhimurium* A1-R on other tumor types [26–47].

We have previously demonstrated efficacy of *S. typhimurium* A1-R in combination with anti-angiogenesis therapy in pancreatic cancer mouse models [37]. Future experiments will also test this combination in colon-cancer liver-metastasis models.

*S. typhimurium* A1-R in combination with chemotherapy was also active against stomach and pancreatic cancer models [35, 40]. Such strategies will also be tested on colon-cancer liver-metastasis in future experiments.

The present study used GFP and RFP to image *S. typhimurium* A1-R and the cancer cells, respectively, *in vitro* and *in vivo*. Genetic reporters have an important advantage over injectable probes in that the label is permanent with genetic reporters. This is important for long-term monitoring of bacterial targeting as well as tumor growth, including metastasis as well as recurrence [48].



**Figure 1: *In vitro* efficacy of *S. typhimurium* A1-R-GFP on HT-29-RFP colon cancer cells.** A–C. Confocal imaging of HT-29-RFP cells with *S. typhimurium* A1-R-GFP over time with the FV1000 confocal microscope. *S. typhimurium* A1-R infection of HT-29-RFP cells at one hour after administration (B) At 15 hour after administration, more bacterial cells were visualized in cancer cells (C). Arrows show infecting *S. typhimurium* A1-R expressing GFP. *S. typhimurium* A1-R inhibited cell proliferation both in colony area **D**, and number **E**. \*\* $P < 0.01$ . Error bars:  $\pm 1$  SE. Scale bars: 20  $\mu\text{m}$  (BF, bright-field). The cells in Figures 1A, B and C were chosen as before and after examples of infection with *S. typhimurium* A1-R-GFP, not to indicate efficacy, which occurs at later times.


Bacteria have numerous advantages over other biological therapy in that bacteria actively invade tumors, even when vascularity is poor and have a large genome to manipulate for effective and selective tumor targeting [2].

Previously developed concepts and strategies of highly selective tumor targeting [49–53] can take advantage of bacterial targeting of tumors.

Tissue-selective therapy focuses on unique properties of normal tissues and how therapy can target a property of a tissue that kills the cancer tissues that arise from the normal tissue without affecting other tissues [49, 54]. *S. typhimurium* A1-R is an example of tissue-selective therapy.

De-differentiation of a tumor leading to resistance to chemotherapy is a limitation of tissue-selective therapy,

since the targeted protein or pathway may no longer be expressed in the de-differentiated tumor [54]. However, *S. typhimurium* A1-R does not seem to depend on such targets and should be active against de-differentiated tumors. Specific caspase inhibitors may protect normal cells which may not be present in drug-resistant cancer cells and those could provide further protection to normal cells during *S. typhimurium* A1-R therapy [49, 51]. *S. typhimurium* A1-R may also be effectively combined with teratogens which could selectively effect cancer cells that are de-differentiated [50]. Since *S. typhimurium* A1-R can decoy quiescent cancer cells to begin to cycle, *S. typhimurium* A1-R could be effectively combined with agents which selectively target proliferating cancer cells [52]. In this regard, normal cells could be protected by agents which induce wild type p53 [53].



**Figure 2: Efficacy of *S. typhimurium* A1-R on HT-29-RFP subcutaneous tumor growth.** Subcutaneous tumor models were established by injection of HT-29-RFP cells in the flanks of nude mice. **A–C.** Upper panels show bright-field images of tumor growth and lower show RFP images of tumor growth obtained with the OV-100 Small Animal Imaging System. An HT-29-RFP subcutaneous tumor in the right flank before treatment (day 1) (A), and after treatment with *S. typhimurium* A1-R at day 22 (B), HT-29-RFP tumor in the untreated control group at day-22 (C). **D.** *S. typhimurium* A1-R administration significantly decreased tumor volume at day-22 compared to no treatment. **E–H.** Representative histological images of excised tumors. *S. typhimurium* A1-R treated tumors had scattered necrosis surrounding viable cancer (E), (F). In contrast, untreated tumors had less necrosis (G), (H). (F) and (H) are high-magnification images of (E) and (G), respectively. \* $P < 0.05$ . Error bars:  $\pm 1$  SE. Arrows show necrotic areas. Scale bars: 20 mm (A) – (C), 500  $\mu$ m (E) and (G), 200  $\mu$ m (F) and (H).

## MATERIALS AND METHODS


### Cell line

The human colon cancer cell line HT-29 [55, 56] was maintained in DMEM (Irvine Scientific, Irvine, CA) supplemented with heat-inactivated 10% fetal bovine serum (FBS) (Gemini Biologic Products, Calabasas, CA), 2 mM glutamine, 100 units/ml penicillin, 100  $\mu$ g/ml streptomycin, and 0.25  $\mu$ g/ml amphotericin B (Life Technologies, Inc., Grand Island, NY). The cells were incubated at 37°C in 5% CO<sub>2</sub>. Expression of RFP indicated viability.


### Establishment of RFP-labeled HT29

The pDsRed-2 vector (Clontech Laboratories Inc., Palo Alto, CA) expressing RFP and neomycin resistance

gene were used to transfect HT-29 to stably express RFP. For RFP gene transfection, 25% confluent HT-29 cells were incubated with a mixture of retroviral supernatants of PT67-RFP packaging cells and DMEM for 24 h. Fresh medium was replenished at this time, and cells were allowed to grow in the absence of retrovirus for 12 h. This procedure was repeated until high levels of RFP expression were achieved. Cells were then harvested with trypsin-EDTA and subcultured into selective medium that contained 200  $\mu$ g/ml G418 (Invitrogen Corp., Carlsbad, CA). The level of G418 was increased to 2,000  $\mu$ g/ml stepwise. HT-29 clones expressing high levels of RFP were isolated and were amplified and transferred using conventional culture methods. High RFP-expression clones were subsequently isolated in the absence of G418 for 10 passages to select for stable expression of RFP [55, 57, 58].



**Figure 3: Intravital imaging of tumor-targeting *S. typhimurium* A1-R in HT-29 liver metastasis.** *S. typhimurium* A1-R-GFP was visualized in the HT-29-RFP liver metastases at day 11 (three days after the second administration of *S. typhimurium* A1-R-GFP). **A.** Liver metastases were visualized with the OV100. **B–D.** Confocal imaging with the FV1000 demonstrated *S. typhimurium* A1-R-GFP targeting the HT-29-RFP liver metastasis. Scale bars: 5 mm (A), and 50  $\mu$ m (B)–(D).



**Figure 4: Efficacy of *S. typhimurium* A1-R on HT-29-RFP liver metastasis.** **A, B.** Upper panels are bright-field and lower panels are RFP images. Images of liver metastasis at day-22. No treatment (control group; A) and treated with *S. typhimurium* A1-R (*S. typhimurium* A1-R group; B). **C.** Bar graphs demonstrates the ratio of tumor fluorescent area at day 22 to day 1. Metastasis growth in the A1-R group was significantly inhibited compared to the untreated control group.  $**P < 0.01$ . Scale bars: 5 mm.

#### Mice

Athymic *nu/nu* nude mice (AntiCancer Inc., San Diego, CA), 4–6 weeks old, were used in this study. All mouse surgical procedures and imaging were performed

with the animals anesthetized by subcutaneous injection of a ketamine mixture (0.02 ml solution of 20 mg/kg ketamine, 15.2 mg/kg xylazine, and 0.48 mg/kg acepromazine maleate). All animal studies were conducted in accordance with the principles and procedures outlined

in the National Institutes of Health Guide for the Care and Use of Animals under Assurance Number A3873-1.

### Preparation of *S. typhimurium* A1-R

GFP-expressing *S. typhimurium* A1-R bacteria (AntiCancer Inc.,) were grown overnight on LB medium (Fisher Sci., Hanover Park, IL, USA) and then diluted 1:10 in LB medium. Bacteria were harvested at late-log phase, washed with PBS, and then diluted in PBS [28].

### Clonogenic assay

HT-29-RFP cells ( $2.0 \times 10^2$ ) were seeded in 35 mm dishes. *S. typhimurium* A1-R-GFP ( $5 \times 10^5$  CFU/ml) was added to the cancer cells, which were incubated at 37°C for 40 minutes. The cells were rinsed and cultured in medium containing gentamycin (10 µg/ml). After 9 days culture, the colonies were fixed with methanol and stained with crystal violet. The Image J program v1.49f (National Institutes of Health) was used to quantify the colonies.

### Confocal imaging of cancer cells infected by *S. typhimurium* A1-R

HT-29-RFP cells ( $4.0 \times 10^4$ ) were seeded in 35 mm dishes. *S. typhimurium* A1-R-GFP ( $5 \times 10^5$  CFU/ml) was added to the cancer cells, which were incubated at 37°C for 40 minutes. The cells were rinsed and cultured in medium containing gentamycin (10 µg/ml). The interaction between *S. typhimurium* A1-R expressing GFP and HT-29 cancer cells expressing RFP was imaged in real time by confocal microscopy (Fluoview FV1000, Olympus Corp., Tokyo, Japan) [59] before, and 1 hour and 15 hours after administration of *S. typhimurium* A1-R.

### Efficacy of *S. typhimurium* A1-R on HT-29 subcutaneous tumors

HT-29-RFP cells were harvested by trypsinization and washed with serum-free medium. A cell suspension ( $2 \times 10^6$  cells/100 µl in medium with 50% Matrigel) was injected subcutaneously in the right flank of nude mice. Two weeks after cell injection, established subcutaneous tumors were measured weekly and treated. Fourteen mice were randomized into a control group ( $n = 7$ ) and an *S. typhimurium* A1-R treatment group ( $n = 7$ ). The first treatment day was defined as day 1. Mice in the *S. typhimurium* A1-R group were treated with *S. typhimurium* A1-R ( $5 \times 10^7$  CFU/body) 3 times at days 1, 8, and 15. All tumors in both groups were observed weekly with the OV100 Small Animal Imaging System (Olympus) [60] and harvested at day 22 for tissue

evaluation. Each tumor was measured individually in each mouse. Tumor volume was calculated with the following formula: Tumor volume =  $1/2 \times \text{Length} \times \text{Width}^2$ . Treatment efficacy was presented as a ratio of the tumor volume at each time point compared to the tumor volume at the beginning of the treatment. Dosing was determined from efficacy in other tumor models of *S. typhimurium* A1-R [26–47].

### Initial establishment of liver metastases

HT-29-RFP cells were harvested by trypsinization and washed twice with serum-free medium. HT-29-RFP cells ( $5 \times 10^5$  in 50 µl serum-free medium with 50% Matrigel) were injected into the superior and inferior pole of the spleen in nude mice. Three weeks after injection, liver metastases were established (Figure 5A).

### Surgical orthotopic implantation of liver metastasis


Liver metastases, as described above, were resected and cut into block (8 mm<sup>3</sup>) (Figure 5B). A single tumor fragment was orthotopically implanted into the left lobe of the liver in other nude mice (Figure 5C). Four weeks later, liver metastasis were observed at the implanted site (Figure 5D).

### Efficacy of *S. typhimurium* A1-R on liver metastasis

Four weeks after orthotopic implantation of HT-29-RFP to the liver, 10 mice were randomized into 2 groups: untreated control group (weekly, 3 weeks,  $n = 5$ ) and the *S. typhimurium* A1-R treatment group (*S. typhimurium* A1-R,  $5 \times 10^7$  CFU/body, iv, weekly, 3 weeks,  $n = 5$ ). The left lobe of the liver with metastasis was exposed before (at day 1) and after treatment (at day 22) for observation with the OV100. The tumor fluorescence area was analyzed with ImageJ software. Treatment efficacy in each mouse was compared as a ratio of the tumor volume at each time point compared to the tumor volume at the beginning of treatment. Liver metastasis in the *S. typhimurium* A1-R treatment group was imaged with the FV1000 confocal microscope at day 11 to observe *S. typhimurium* A1-R-GFP targeting the RFP-expressing HT-29 liver metastasis.

### Histology of tissue

Fresh tumor samples were fixed in formalin (10%) and embedded in paraffin before sectioning and staining. Tissue sections (3 mm) were deparaffinized in xylene and rehydrated in an ethanol series. Hematoxylin and eosin (H & E) staining was performed according to standard protocols.



**Figure 5: Establishment of orthotopic liver metastasis mouse models.** Upper panels show bright-field images and lower are RFP images. **A.** Multiple liver metastases were initially established after spleen injection of HT-29-RFP cells in the donor mouse. **B.** The metastases were resected and cut into small fragments. **C.** Single fragments were then orthotopically implanted in the left lobe of the liver in the experimental mice through an incision (arrow). **D.** Four weeks after implantation, an orthotopic liver metastasis mouse model was established. Scale bars: 3 mm.

### Statistical analysis

SPSS statistics version 21.0 was used for all statistical analyses (IBM, New York City, NY, USA). Significant differences for continuous variables were determined using the Mann-Whitney *U* test. Bar graphs expressed average values and error bar showed SE. A probability value of  $P \leq 0.05$  was considered statistically significant.

### ACKNOWLEDGMENTS

This study was supported by National Cancer Institute grant numbers CA132971 and CA142669 and JSPS KAKENHI grant numbers 26830081 to YH, 26462070 to IE and 24592009 to KT. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

### CONFLICTS OF INTEREST

M.Z. and Y.Z. are employees of AntiCancer Inc. T.M., Y.H. and R.M.H. are unsalaried associates of AntiCancer Inc. There are no other competing financial interests.

### Dedication

This paper is dedicated to the memory of A.R. Moossa, M.D.

### REFERENCES

1. William Coley. Available at: [http://en.wikipedia.org/wiki/William\\_Coley](http://en.wikipedia.org/wiki/William_Coley) [last accessed 12 December 2013].
2. Forbes NS. Engineering the perfect (bacterial) cancer therapy. *Nat Rev Cancer*. 2010; 10:785–94.
3. Hoption Cann SA, van Netten JP, van Netten C. Dr William Coley and tumour regression: a place in history or in the future. *Postgrad Med J*. 2003; 79:672–80.
4. Richardson MA, Ramirez T, Russell NC, Moyer LA. Coley toxins immunotherapy: a retrospective review. *Altern Ther Health Med*. 1999; 5:42–7.
5. Malmgren RA, Flanigan CC. Localization of the vegetative form of *Clostridium tetani* in mouse tumors following intravenous spore administration. *Cancer Res*. 1955; 15:473–8.
6. Gericke D, Engelbart K. Oncolysis by clostridia. II. Experiments on a tumor spectrum with a variety of clostridia in combination with heavy metal. *Cancer Res*. 1964; 24:217–21.
7. Moese JR, Moese G. Oncolysis by clostridia. I. Activity of *Clostridium butyricum* (M-55) and other nonpathogenic clostridia against the Ehrlich carcinoma. *Cancer Res*. 1964; 24:212–6.
8. Thiele EH, Arison RN, Boxer GE. Oncolysis by clostridia. III. Effects of clostridia and chemotherapeutic agents on rodent tumors. *Cancer Res*. 1964; 24:222–33.

9. Kohwi Y, Imai K, Tamura Z, Hashimoto Y. Antitumor effect of *Bifidobacterium infantis* in mice. *Gan*. 1978; 69:613–8.
10. Kimura NT, Taniguchi S, Aoki K, Baba T. Selective localization and growth of *Bifidobacterium bifidum* in mouse tumors following intravenous administration. *Cancer Res*. 1980; 40:2061–8.
11. Fox ME, Lemmon MJ, Mauchline ML, Davis TO, Giaccia AJ, Minton NP, Brown JM. Anaerobic bacteria as a delivery system for cancer gene therapy: *in vitro* activation of 5-fluorocytosine by genetically engineered clostridia. *Gene Ther*. 1996; 3:173–8.
12. Lemmon MJ, Van Zijl P, Fox ME, Mauchline ML, Giaccia AJ, Minton NP, Brown JM. Anaerobic bacteria as a gene delivery system that is controlled by the tumor microenvironment. *Gene Ther*. 1997; 4:791–6.
13. Brown JM, Giaccia AJ. The unique physiology of solid tumors: opportunities (and problems) for cancer therapy. *Cancer Res*. 1998; 58:1408–16.
14. Low KB, Ittensohn M, Le T, Platt J, Sodi S, Amoss M, Ash O, Carmichael E, Chakraborty A, Fischer J, Lin SL, Luo X, Miller SI, Zheng L, King I, Pawelek JM, Bermudes D. Lipid A mutant *Salmonella* with suppressed virulence and TNF $\alpha$  induction retain tumor-targeting *in vivo*. *Nat Biotechnol*. 1999; 17:37–41.
15. Clairmont C, Lee KC, Pike J, Ittensohn M, Low KB, Pawelek J, Bermudes D, Brecher SM, Margitich D, Turnier J, Li Z, Luo X, King I, Zheng LM. Biodistribution and genetic stability of the novel antitumor agent VNP20009, a genetically modified strain of *Salmonella typhimurium*. *J Infect Dis*. 2000; 181:1996–2002.
16. Sznol M, Lin SL, Bermudes D, Zheng LM, King I. Use of preferentially replicating bacteria for the treatment of cancer. *J Clin Invest*. 2000; 105:1027–30.
17. Yazawa K, Fujimori M, Nakamura T, Sasaki T, Amano J, Kano Y, Taniguchi S. *Bifidobacterium longum* as a delivery system for gene therapy of chemically induced rat mammary tumors. *Breast Cancer Res Treat*. 2001; 66:165–70.
18. Dang LH, Bettgowda C, Huso DL, Kinzler KW, Vogelstein B. Combination bacteriolytic therapy for the treatment of experimental tumors. *Proc Natl Acad Sci USA*. 2001; 98:15155–60.
19. Roberts NJ, Zhang L, Janku F, Collins A, Bai RY, Staedtke V, Rusk AW, Tung D, Miller M, Roix J, Khanna KV, Murthy R, Benjamin RS, Helgason T, Szvalb AD, Bird JE, Roy-Chowdhuri S, Zhang HH, Qiao Y, Karim B, McDaniel J, Elpiner A, Sahara A, Lachowicz J, Phillips B, Turner A, Klein MK, Post G, Diaz LA Jr, Riggins GJ, Papadopoulos N, Kinzler KW, Vogelstein B, Bettgowda C, Huso DL, Varterasian M, Saha S, Zhou S. Intratumoral injection of *Clostridium novyi*-NT spores induces antitumor responses. *Sci Transl Med*. 2014; 6:249ra111.
20. Pawelek JM, Low KB, Bermudes D. Bacteria as tumour-targeting vectors. *Lancet Oncol*. 2003; 4:548–56.
21. Pawelek JM, Low KB, Bermudes D. Tumor-targeted *Salmonella* as a novel anticancer vector. *Cancer Res*. 1997; 57:4537–44.
22. Toso JF, Gill VJ, Hwu P, Marincola FM, Restifo NP, Schwartzentruber DJ, Sherry RM, Topalian SL, Yang JC, Stock F, Freezer LJ, Morton KE, Seipp C, Haworth L, Mavroukakis S, White D, MacDonald S, Mao J, Sznol M, Rosenberg SA. Phase I study of the intravenous administration of attenuated *Salmonella typhimurium* to patients with metastatic melanoma. *J Clin Oncol*. 2002; 20:142–52.
23. Rothbarth J, van de Velde CJ. Treatment of liver metastases of colorectal cancer. *Ann Oncol*. 2005; 16:ii144–9.
24. de Jong MC, Pulitano C, Ribero D, Strub J, Mentha G, Schulick RD, Choti MA, Aldrighetti L, Capussotti L, Pawlik TM. Rates and patterns of recurrence following curative intent surgery for colorectal liver metastasis: an international multi-institutional analysis of 1669 patients. *Ann Surg*. 2009; 250:440–8.
25. Zhang W, Song T. The progress in adjuvant therapy after curative resection of liver metastasis from colorectal cancer. *Drug Discov Ther*. 2014; 8:194–20.
26. Zhao M, Yang M, Li XM, Jiang P, Baranov E, Li S, Xu M, Penman S, Hoffman RM. Tumor-targeting bacterial therapy with amino acid auxotrophs of GFP-expressing *Salmonella typhimurium*. *Proc Natl Acad Sci USA*. 2005; 102:755–60.
27. Zhao M, Geller J, Ma H, Yang M, Penman S, Hoffman RM. Monotherapy with a tumor-targeting mutant of *Salmonella typhimurium* cures orthotopic metastatic mouse models of human prostate cancer. *Proc Natl Acad Sci USA*. 2007; 104:10170–4.
28. Zhao M, Yang M, Ma H, Li X, Tan X, Li S, Yang Z, Hoffman RM. Targeted therapy with a *Salmonella typhimurium* leucine-arginine auxotroph cures orthotopic human breast tumors in nude mice. *Cancer Res*. 2006; 66:7647–52.
29. Zhang Y, Tome Y, Suetsugu A, Zhang L, Zhang N, Hoffman RM, Zhao M. Determination of the optimal route of administration of *Salmonella typhimurium* A1-R to target breast cancer in nude mice. *Anticancer Res*. 2012; 32:2501–8.
30. Zhang Y, Miwa S, Zhang N, Hoffman RM, Zhao M. Tumor-targeting *Salmonella typhimurium* A1-R arrests growth of breast-cancer brain metastasis. *Oncotarget*. 2015; 6:2615–22.
31. Uchugonova A, Zhao M, Zhang Y, Weinigel M, König K, Hoffman RM. Cancer-cell killing by engineered *Salmonella* imaged by multiphoton tomography in live mice. *Anticancer Res*. 2012; 32:4331–8.
32. Liu F, Zhang L, Hoffman RM, Zhao M. Vessel destruction by tumor-targeting *Salmonella typhimurium* A1-R is enhanced by high tumor vascularity. *Cell Cycle*. 2010; 9:4518–24.



33. Nagakura C, Hayashi K, Zhao M, Yamauchi K, Yamamoto N, Tsuchiya H, Tomita K, Bouvet M, Hoffman RM. Efficacy of a genetically-modified *Salmonella typhimurium* in an orthotopic human pancreatic cancer in nude mice. *Anticancer Res.* 2009; 29:1873–8.
34. Yam C, Zhao M, Hayashi K, Ma H, Kishimoto H, McElroy M, Bouvet M, Hoffman RM. Monotherapy with a tumor-targeting mutant of *S. typhimurium* inhibits liver metastasis in a mouse model of pancreatic cancer. *J Surg Res.* 2010; 164:248–55.
35. Hiroshima Y, Zhao M, Zhang Y, Maawy A, Hassanein MK, Uehara F, Miwa S, Yano S, Momiyama M, Suetsugu A, Chishima T, Tanaka K, Bouvet M, Endo I, Hoffman RM. Comparison of efficacy of *Salmonella typhimurium* A1-R and chemotherapy on stem-like and non-stem human pancreatic cancer cells. *Cell Cycle.* 2013; 12:2774–80.
36. Hiroshima Y, Zhao M, Maawy A, Zhang Y, Katz MH, Fleming JB, Uehara F, Miwa S, Yano S, Momiyama M, Suetsugu A, Chishima T, Tanaka K, Bouvet M, Endo I, Hoffman RM. Efficacy of *Salmonella typhimurium* A1-R versus chemotherapy on a pancreatic cancer patient-derived orthotopic xenograft (PDOX). *J Cell Biochem.* 2014; 115:1254–61.
37. Hiroshima Y, Zhang Y, Murakami T, Maawy AA, Miwa S, Yamamoto M, Yano S, Sato S, Momiyama M, Mori R, Matsuyama R, Chishima T, Tanaka K, Ichikawa Y, Bouvet M, Endo I, Zhao M, Hoffman RM. Efficacy of tumor-targeting *Salmonella typhimurium* A1-R in combination with anti-angiogenesis therapy on a pancreatic cancer patient-derived orthotopic xenograft (PDOX) and cell line mouse models. *Oncotarget.* 2014; 5:12346–57.
38. Matsumoto Y, Miwa S, Zhang Y, Hiroshima Y, Yano S, Uehara F, Yamamoto M, Toneri M, Bouvet M, Matsubara H, Hoffman RM, Zhao M. Efficacy of tumor-targeting *Salmonella typhimurium* A1-R on nude mouse models of metastatic and disseminated human ovarian cancer. *J Cell Biochem.* 2014; 115:1996–2003.
39. Matsumoto Y, Miwa S, Zhang Y, Zhao M, Yano S, Uehara F, Yamamoto M, Hiroshima Y, Toneri M, Bouvet M, Matsubara H, Tsuchiya H, Hoffman RM. Intraperitoneal administration of tumor-targeting *Salmonella typhimurium* A1-R inhibits disseminated human ovarian cancer and extends survival in nude mice. *Oncotarget.* 2015; 6:11369–77.
40. Yano S, Zhang Y, Zhao M, Hiroshima Y, Miwa S, Uehara F, Kishimoto H, Tazawa H, Bouvet M, Fujiwara T, Hoffman RM. Tumor-targeting *Salmonella typhimurium* A1-R decoys quiescent cancer cells to cycle as visualized by Fucci imaging and become sensitive to chemotherapy. *Cell Cycle.* 2014; 13:3958–63.
41. Hiroshima Y, Zhang Y, Zhao M, Zhang N, Murakami T, Maawy A, Mii S, Uehara F, Yamamoto M, Miwa S, Yano S, Momiyama M, Mori R, Matsuyama R, Chishima T, Tanaka K, Ichikawa Y, Bouvet M, Endo I, Hoffman RM. Tumor-targeting *Salmonella typhimurium* A1-R in combination with Trastuzumab eradicates HER-2-positive cervical cancer cells in patient-derived mouse models. *PLoS One.* 2015; 10:e0120358.
42. Hayashi K, Zhao M, Yamauchi K, Yamamoto N, Tsuchiya H, Tomita K, Hoffman RM. Cancer metastasis directly eradicated by targeted therapy with a modified *Salmonella typhimurium*. *J Cell Biochem.* 2009; 106:992–8.
43. Hayashi K, Zhao M, Yamauchi K, Yamamoto N, Tsuchiya H, Tomita K, Kishimoto H, Bouvet M, Hoffman RM. Systemic targeting of primary bone tumor and lung metastasis of high-grade osteosarcoma in nude mice with a tumor-selective strain of *Salmonella typhimurium*. *Cell Cycle.* 2009; 8:870–5.
44. Tome Y, Zhang Y, Momiyama M, Maehara H, Kanaya F, Tomita K, Tsuchiya H, Bouvet M, Hoffman RM, Zhao M. Primer dosing of *S. typhimurium* A1-R potentiates tumor-targeting and efficacy in immunocompetent mice. *Anticancer Res.* 2013; 33:97–102.
45. Miwa S, Zhang Y, Baek K-E, Uehara F, Yano S, Yamamoto M, Hiroshima Y, Matsumoto Y, Kimura H, Hayashi K, Yamamoto N, Tsuchiya H, Hoffman RM, Zhao M. Inhibition of spontaneous and experimental lung metastasis of soft-tissue sarcoma by tumor-targeting *Salmonella typhimurium* A1-R. *Oncotarget.* 2014; 5:12849–61.
46. Kimura H, Zhang L, Zhao M, Hayashi K, Tsuchiya H, Tomita K, Bouvet M, Wessels J, Hoffman RM. Targeted therapy of spinal cord glioma with a genetically-modified *Salmonella typhimurium*. *Cell Proliferation.* 2010; 43:41–8.
47. Momiyama M, Zhao M, Kimura H, Tran B, Chishima T, Bouvet M, Endo I, Hoffman RM. Inhibition and eradication of human glioma with tumor-targeting *Salmonella typhimurium* in an orthotopic nude-mouse model. *Cell Cycle.* 2012; 11:628–32.
48. Kishimoto H, Aki R, Urata Y, Bouvet M, Momiyama M, Tanaka N, Fujiwara T, Hoffman RM. Tumor-selective adenoviral-mediated GFP genetic labeling of human cancer in the live mouse reports future recurrence after resection. *Cell Cycle.* 2011; 10:2737–2741.
49. Blagosklonny MV. Matching targets for selective cancer therapy. *Drug Discov Today.* 2003; 8:1104–7.
50. Blagosklonny MV. Teratogens as anti-cancer drugs. *Cell Cycle.* 2005; 4:1518–21.
51. Blagosklonny MV. Treatment with inhibitors of caspases, that are substrates of drug transporters, selectively permits chemotherapy-induced apoptosis in multidrug-resistant cells but protects normal cells. *Leukemia.* 2001; 15:936–41.
52. Blagosklonny MV. Target for cancer therapy: proliferating cells or stem cells. *Leukemia.* 2006; 20:385–91.
53. Apontes P, Leontieva OV, Demidenko ZN, Li F, Blagosklonny MV. Exploring long-term protection

- of normal human fibroblasts and epithelial cells from chemotherapy in cell culture. *Oncotarget*. 2011; 2:222–33.
54. Blagosklonny MV. Tissue-selective therapy of cancer. *Br J Cancer*. 2003; 89:1147–51.
  55. Maawy AA, Hiroshima Y, Zhang Y, Luiken GA, Hoffman RM, Bouvet M. Polyethylene glycol (PEG) linked to near infrared (NIR) dyes conjugated to chimeric anti-carcinoembryonic antigen (CEA) antibody enhances imaging of liver metastases in a nude-mouse model of human colon cancer. *PLoS One*. 2014; 9:e97965.
  56. Ma H, Li X, Yang Z, Okuno S, Kawaguchi T, Yagi S, Bouvet M, Hoffman RM. High antimetastatic efficacy of MEN4901/T-0128, a novel camptothecin carboxymethyldextran conjugate. *J Surg Res*. 2011; 171:684–90.
  57. Katz MH, Takimoto S, Spivack D, Moossa AR, Hoffman RM, Bouvet M. A novel red fluorescent protein orthotopic pancreatic cancer model for the preclinical evaluation of chemotherapeutics. *J Surg Res*. 2003; 113:151–60.
  58. Metildi CA, Kaushal S, Snyder CS, Hoffman RM, Bouvet M. Fluorescence-guided surgery of human colon cancer increases complete resection resulting in cures in an orthotopic nude mouse model. *J Surg Res*. 2013; 179:87–93.
  59. Uchugonova A, Zhao M, Weinigel M, Zhang Y, Bouvet M, Hoffman RM, Koenig K. Multiphoton tomography visualizes collagen fibers in the tumor micro-environment that maintain cancer-cell anchorage and shape. *J Cell Biochem*. 2013; 114:99–102.
  60. Yamauchi K, Yang M, Jiang P, Xu M, Yamamoto N, Tsuchiya H, Tomita K, Moossa AR, Bouvet M, Hoffman RM. Development of real-time subcellular dynamic multicolor imaging of cancer-cell trafficking in live mice with a variable-magnification whole-mouse imaging system. *Cancer Res*. 2006; 66:4208–14.